WallStSmart
TBPH

Theravance Biopharma Inc

NASDAQ: TBPH · HEALTHCARE · BIOTECHNOLOGY

$16.52
-2.88% today

Updated 2026-05-11

Market cap
$876.78M
P/E ratio
7.63
P/S ratio
7.99x
EPS (TTM)
$2.23
Dividend yield
52W range
$8 – $21
Volume
0.6M

Theravance Biopharma Inc (TBPH) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
-36.4%
Last 4 quarters
Revenue YoY growth
+144.7%
Most recent quarter
EPS YoY growth
+217.8%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+8.1%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
+25.4%
2025-11-10
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-04$0.06-94.1%$13.96$13.58-2.7%
2025-11-10$0.07+153.8%$14.75$18.50+25.4%
2025-08-04$-0.08-112.5%$10.90$11.09+1.7%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$1.00$0.06-94.1%$45.89M+144.7%
2025-09-30$-0.13$0.07+153.8%$19.99M+18.5%
2025-06-30$0.67$-0.08-112.5%$26.20M+83.7%
2025-03-31$-0.09$-0.17-92.7%$15.39M+6.1%
2024-12-31$-0.08$-0.05+39.9%$18.75M+6.8%
2024-09-30$-0.23$-0.06+74.3%$16.87M+7.5%
2024-06-30$-0.21$-0.28-33.3%$14.26M+3.7%
2024-03-31$-0.25$-0.24+4.0%$14.50M
2023-12-31$-0.15$-0.17-13.3%$17.57M
2023-09-30$-0.21$-0.17+19.0%$15.69M
2023-06-30$-0.21$-0.28-33.3%$13.75M

Frequently asked questions

Has Theravance Biopharma Inc beaten earnings estimates?
Theravance Biopharma Inc has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of -36.4% over the last 4 quarters.
How does TBPH stock react to earnings?
TBPH stock has moved an average of +8.1% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is Theravance Biopharma Inc's revenue growth rate?
Theravance Biopharma Inc reported year-over-year revenue growth of +144.7% in its most recent quarter, with EPS growing +217.8% year-over-year.